Original Research Article

ELECTROMYOGRAPHIC FINDINGS IN GUILLAIN-BARRÉ SYNDROME PATIENTS

ABSTRACT

OBJECTIVE: To determine electromyographic findings in Guillain-barré syndrome patients.

SETTING AND DURATION STUDY: This is a descriptive cross-sectional study conducted in the Neuromedicine departments of tertiary care Hospital JPMC, from1st February 2020 to 30th July 2021

MATERIALS AND METHODS: GBS was diagnosed according to the diagnostic criteria from the National Institute of Neurological Disorders and Stroke (NINDS) in 1990. All patients gave consent to and underwent electromyographic assessment with a Keypoint evoked muscle potential equipment at admission and 2, 3, and 6 months post disease onset. The records of the patients were anonymized and deidentified before analysis.

RESULTS: The Age range in this study was from 13 to 70 years with a mean age of 36.58±16.0 years . 63% of patients were of male gender and 37% of patients were female. The frequency of Electromyographic findings were acute demyelinating polyneuropathy in 73% of cases, acute sensorimotor axonal polyneuropathy 14% of cases, acute motor xonal polyneuropathy 12% of cases and acute sensory polyneuropathy 1% case.

CONCLUSION: The electromyography plays a role to diagnose GBS but along with this NCV and CSF analysis are also helpful in diagnosis and prognosis prediction.

KEY WORDS : Guillain-barré syndrome, Electromyographic, Autoimmune disorder

INTRODUCTION:

Guillian-Barre syndrome (GBS) is a rare, autoimmune disorder(1) characterized by acute immune-mediated polyneuropathy comprised of rapidly progressive flaccid paralysis which is symmetrical and ascending in nature and a reflexic (2). GBS has been associated with many infections. Respiratory and gastrointestinal illnesses are the two most commonly involved with this disorder. Before the onset of GBS presentation, up to 70% of patients have reported an antecedent illness during 1 to 6 weeks of disease(3). Although post-infectious GBSs have equivocal epidemiological evidence (4). Many bacterias and viruses are linked with GBS including Campylobacter jejuni, Mycoplasma pneumoniae, and Haemophilus influenzae, among viruses are Cytomegalovirus(CMV), influenza, enteroviruses, Ebstein barr virus, herpes simplex virus, hepatitis, human immunodeficiency virus and Zika virus(5,6). It has been noted that molecular mimicry plays a crucial role in the establishment of GBS , particularly the axonal variant. The gangliosides of peripheral nerves show similarities with lipopolysaccharides of campylobacter jejuni. Therefore an immune response generated against infectious agents cross react with nerve sheath (7). Although it is a rare disorder, has an annual incidence of 0.4 to 2 per 100,000 persons, Guillian-Barre Syndrome has a major impact on the health care system. An estimated cost of treatment for a patient with GBS is up to $318,966. The overall cost of medical care for patients with GBS is estimated up to $1.7 billion per year. GBS can affect all ages but incidences are more common in males than in female. It has been estimated that 100,000 patients would contract GBS worldwide annually(4,8). The most common symptom of GBS is ascending paralysis which starts first as symmetrical leg weakness(9,10). In addition, GBS patients develop weakness of extremities, body, and weakness of cranial nerves in just few hours or few days of onset of symptoms (11,12), and the effects on lower limbs are more prominent and dangerous than on upper limbs, which finally causes flaccid paresis and weak or even absent deep tendon reflex. Sometimes in the early stages of GBS absent tendon reflex, dysfunction, and even aphasia develop in pediatric patients(13,14,15). Guillian-Barre Syndrome consists of the spectrum of immune-mediated polyneuropathy that can be divisible into several subtypes depending upon clinical features and electrophysiological findings, including acute inflammatory demyelinating polyneuropathy(AIDP), acute motor axonal neuropathy (AMAN) (16), and acute motor-sensory axonal neuropathy (AMSAN), and comprises the clinical variant of GBS Miller-Fisher Syndrome (MFS), and Bickerstaff's brainstem encephalitis(8,17). The predominant form of GBS in North America and Europe is acute inflammatory demyelinating axonal polyneuropathy (AIDP). The less prominent form the axonal form accounts for only 5% of patients including acute motor axonal neuropathy (AMAN). Patients with the axonal form of GBS show the worst of symptoms earlier than those with the demyelinating form. However, the recovery rate can be compared between the two (18). Motor sensory axonal neuropathy shows the worst prognosis and progresses to tetraplegia rapidly (19). In Asia, Central and South America axonal forms account for 30-47% of cases (2). At

present, clinical strategies used for the management of Guillian-Barre syndrome (GBS) are enhanced respiratory management, anti-infective therapy, nutritional care, rehabilitation care, and training, these can immensely improve body dysfunction caused by Guillian-Barre syndrome (GBS) but the results are quite far away from what is expected (20.21). with emerging medical rehabilitation technology, early rehabilitation is crucial to Guillian-Barre syndrome (GBS) treatment, and electromyographic biofeedback therapy is extensively used in preventive medicine(22,23).

Material and Methods

This is a descriptive cross-sectional study conducted in Neuromedicine departments of tertiary care Hospital JPMC, from1st February 2020 to 30th July 2021. Informed consent was taken from patient's relative. Guillian-Barre syndrome (GBS) was diagnosed according tothe diagnostic criteria from the National Institute of Neurological Disorders and Stroke (NINDS) from 1990. The records of the patients were anonymized and deidentified before analysis. The study protocol was approved by the local institutional review board at the authors' affiliated institution and patient consent was not required because of the retrospective nature of the study.

Electromyographic assessment

All patients gave consent to and underwent electromyographic assessment with a Keypoint evoked muscle potential equipment at admission and 2, 3, and 6 months post disease onset. Concentric needle electrodes were used to record abnormally evoked resting potential at the abductor pollicis brevis, abductor digiti minimi, vastus medialis, and tibialis anterior muscle. Motor unit action potential was recorded during mild contraction, and cluster type of motor unit action potential was recorded during intense contraction. Motor nerve conduction study was done by stimulating the median nerve, ulnar nerve, the common peroneal nerve, and the motor branch of the tibial nerve to assess CMAPs including onset latency, amplitude, and conduction velocity. Surface electrodes were used to record the mean conduction velocity (MCV) and distal motor latency (DML) of the median nerve, ulnar nerve, common peroneal nerve, and the motor branch of the tibial nerve. Amplitude was measured in negative peak value. Sensory nerves examined included the median nerve, ulnar nerve, and sural nerve. Sensory conduction velocity was recorded, and sensory nerve action potential (SNAP) amplitude was measured in negative wave value. F wave was recorded off

the median nerve and ulnar nerve. Frequency was recorded. Patient's skin temperature was kept 32°C–35°C with an ambient temperature of 24°C–28°C.

RESULTS

Age range in this study was from 13 to 70 years with mean age of 36.58±16.0 years as shown in Table-1. 63% of patients were of male gender and 37% patients were <mark>female</mark> as shown in Table-1. Frequency of Electromyographic findings were acute <mark>demyelinating</mark> polyneuropathy in 73% cases, acute sensorimotor axonal polyneuropathy 14% cases, acute motor xonal polyneuropathy 12% cases and acute sensory polyneuropathy 1% case.

Acute <mark>demyelinating</mark> polyneuropathy found commonly in all age groups while Acute sensorimotor axonal polyneuropathy and Acute motor xonal polyneuropathy were found mostly 3rd and 4th decay of life, While findings were more common in males (Table No.2 and 3).

Table No.1
Patient's characteristic
(n-100)

Variable	Patients	Percentage
Gender (Male to Female ratio 1.7:1)		
• Male	63	63%
• Female	37	37%
Age in years (Means Age 36.58±16.0 years)		
• 10-20 years	21	21%
• 21-30 years	23	23%
• 31-40 years	20	20%
• 41-50 years	15	15%
• 51-60 years	11	11%
• 61-70 years	10	10%
Electromyographic findings		
• Acute Demyelinating Polyneuropathy	73	73%
• Acute Sensorimotor Axonal Polyneuropathy	14	14%
• Acute Motor Xonal Polyneuropathy	12	12%
• Acute Sensory Polyneuropathy	1	1%

Table No.2
ELECTROMYOGRAPHIC FINDINGS ACCORDING TO GENDER
(n-100)

ELECTROMYOGRAPHIC FINDINGS	GENDER		P-value
	Male Patients(%)	Female Patients(%)	
• Acute Demyelinating Polyneuropathy	47(47%)	26(26%)	0.097
• Acute Sensorimotor Axonal Polyneuropathy	6(6%)	8(8%)	
• Acute Motor Xonal Polyneuropathy	10(10%)	2(2%)	
• Acute Sensory Polyneuropathy	0	1(1%)	

Table No.3
ELECTROMYOGRAPHIC FINDINGS ACCORDING TO AGE
(n-100)

ELECTROMYOGRAPHIC FINDINGS	Age in years					
	10-20	20-30	31-40	41-50	51-60	61-70
• Acute Demyelinating Polyneuropathy	15	14	14	13	9	8
• Acute Sensorimotor Axonal Polyneuropathy	1	4	4	1	2	2
• Acute Motor Xonal Polyneuropathy	4	5	2	1	0	0
• Acute Sensory Polyneuropathy	1	0	0	0	0	0

DISCUSSION:

Guillian-Barre Syndrome has variable annual incidence worldwide ranging from 0.38 to 2.53 per 100,000, with most studies reporting 1.1 to 1.8 per 100,000 (16). The incidence is higher in adults than in children. Males are 1.5 times more frequently affected than female in all age groups (2,25,26).

In our study, we have evaluated 100 patients: 63% of males (63 patients) and 37% of female (37 patients). The age range in our study was from 13 years to 70 years with a mean age of 36.58±16.0 years. Men were more affected than women, but the mean age in our study was not very high. The incidence of Guillian-Barre syndrome (GBS) increases with age. This has also been reported in the international GBS outcome study (IGOS) that recruited 925 patients worldwide f(24). Guillian-Barre Syndrome also increases with age in North America and Europe(2). In our study, only 10% of patients came under the age of 61-70 years of age and 23% of patients were in the age group of 21-30 years of age.). Parallel to our study, patients from Bangladesh were younger, where the median age was 21 years (24). This discrepant distribution between our study and the international study can be described by the variable demography of the general population, antecedent infections, and treatment.

In our study, the prevalence of GBS increased with age, for both males and female. Guillian-Barre syndrome (GBS) in our patients affected a broad range of ages. Corresponding age distribution has been found in a previous study (16,4). The frequency of males for Guillian-Barre syndrome (GBS) in our study was more than female. Male to female ratio in International Guillian-Barre syndrome (GBS) outcome study (IGOS) is 1.5:1(24). Such male to female ratio has also been reported in another study (2,34). Therefore, male gender and increasing age are non-modifiable risk factors for developing Guillian-Barre syndrome (GBS) worldwide. Polyradiculopathy patients have more mean age than any other form and acute motor axonal polyneuropathy has less mean age than any other form. In our study, Acute demyelinating polyneuropathy was found commonly in all age groups while Acute sensorimotor axonal polyneuropathy and Acute motor axonal polyneuropathy were found mostly 3rd and 4th decay of life. This shows a relative proportion to a study where the mean age of patients with acute motor axonal polyneuropathy (2nd decay of life) and acute sensorimotor axonal polyneuropathy is lower than acute demyelinating polyneuropathy (35). The predisposition of acute motor axonal

polyneuropathy in young age group specifically younger than 40 was also observed in another study (36,37). However, in the Northern China epidemic, acute motor axonal polyneuropathy was mostly reported in children(38).

Guillian barre syndrome is a group of heterogeneous syndrome having many different subtypes (27). In our study, Acute demyelinating polyneuropathy was predominantly reported electrophysiological subtype, accounting for 73% of the Guillian-Barre syndrome (GBS) cases. The other prevalent electrophysiological subtypes that came under second and third position were Acute sensorimotor axonal polyneuropathy and acute motor axonal neuropathy, accounting for 14% and 12% of the cases, respectively. Acute sensory axonal polyneuropathy was the least one, accounting for only 1% of the cases. The parallel correspondent is observed in a cohort study in Oman in which 44 patients were included. They had a relative proportion of electrophysiological subtypes as our study, accounting 52% for acute demyelinating polyneuropathy, 30% for acute motor axonal polyneuropathy, and 14% for acute sensorimotor axonal polyneuropathy (28). One more study from Kuwait, a comparatively older study also showed an increased proportion of Acute demyelinating polyneuropathy of about 68%, and decreased proportion of other axonal electrophysiological subtypes (15%) (29). There are two latest retrospective studies from Northern and the Southern China, which have reported different frequencies of electrophysiological subtypes of Guillian-Barre syndrome (GBS). The study conducted in Northern China reported acute motor axonal polyneuropathy as a predominant subtype accounting for 55.8% and acute demyelinating polyneuropathy was relatively less frequent(21.2%) (30). In contrast to Southern China study, a higher proportion of Acute demyelinating polyneuropathy of about 49.0% was reported as compared to a lower proportion of Acute motor axonal polyneuropathy of about 18.8% (14). The corresponding frequencies of GBS subtypes of our study are relatively comparable to Southern China study (14). However, the proportion of acute motor axonal polyneuropathy reported in North America and Europe (3.0%) is still lower than the proportion reported in China and South Arabia (31). The geographical variance in the prevalence of acute motor axonal polyneuropathy and acute demyelinating polyneuropathy may be affected by certain environmental factors, variance in the frequencies, and types of antecedent infections, and genetic polymorphism of Compylobacter jejuni strains. The relative resemblance between our study and the study of Southern China (14) is a representation of the two different ethnic groups, proclaiming against a role of human genetic polymorphism to affect Guillain-Barre Syndrome subtype. Poor recovery

trend has been noted in acute motor axonal polyneuropathy subtype as compared to acute demyelinating polyneuropathy in Europe, America, and Bangladesh(32). In a study in Notherneast China, more severe symptoms had been observed in acute motor axonal polyneuropathy than in acute demyelinating polyneuropathy at admission, but the prognosis between the two was almost similar (33). This demonstrates that the severity of the disease is also varying among different regions just like electrophysiological subtypes. Although the impact of electrophysiological subtypes on prognosis is still under debate, as there is a slow and incomplete recovery in axonal Guillian-Barre syndrome (GBS) because of degeneration of axon, or faster because of conduction block transient recovery, and it may also depend upon criteria of subtypes(34,39).

The region-to-region variation in frequencies of clinical and ==electrophysiological== subtypes of Guillian-Barre syndrome (GBS) can be partly explained by variation in local exposure to infections. The one suggested mechanism is that infection generates an immune response which then cross-reacts with peripheral nerve(molecular mimicry), which then damages the myelin sheath and axons. Campylobacter infection is the most predominant microorganism causing Guillian-Barre syndrome (GBS) (40).

CONCLUSION:

The study demonstrated frequency, sex distribution, and age distribution of Guillian Barre Syndrome similar to other studies. In our study, the most predominant type of GBS was acute demyelinating polyneuropathy. Acute motor axonal and acute sensorimotor axonal polyneuropathy were in the second and third distribution. Mean age was lower in our study with males predominant. Electromyography plays a role to diagnose GBS but along with this NCV and CSF analysis are also helpful in diagnosis and prognosis prediction.

Ethical Approval:

As per international standard or university standard written ethical approval has been collected and preserved by the author(s).

Consent

As per international standard or university standard, patients' written consent has been collected and preserved by the author(s).

REFERENCES:

1.   Guillian-Barre Syndrome. Available online. https://www.cdc.gov/campylobacter/Guillain-barre.html

2.   Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005 Nov;366(9497):1653-66.

3.   Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014 Jan;137(Pt 1):33-43.

4.   Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain−Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123-133.

5.   Wakerley BR, Yuki N. Infectious and noninfectious triggers in Guillain−Barré syndrome. Expert Rev Clin Immunol. 2013;9(7):627-639.

6.   Dalakas MC. Guillain−Barré syndrome: the first documented COVID-19-triggered autoimmune neurologic disease: more to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e781.

7.   Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Miyatake T. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med. 1993 Nov 01;178(5):1771-5.

8.   Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016 Aug 13;388(10045):717-27.

9.   Tan H. J. Alyaa H. K., Soong C., Tan H. J. A case of Guillain-Barre syndrome (GBS) presenting with acute urinary retention and T6 sensory level. Clinical Medicine: Journal of the Royal College of Physicians of London . 2018;18(4):308–310.

10.   Halpin A. L., Gu W., Wise M. E., Sejvar J. J., Hoekstra R. M., Mahon B. E. Post-Campylobacter Guillain Barré Syndrome in the USA: secondary analysis of surveillance data collected during the 2009-2010 novel Influenza A (H1N1) vaccination campaign. Epidemiology and Infection . 2018;146(13):1740–1745.

11.   Liu X., Jin J., Dang Y. Very early neurophysiological study in Guillain-barre syndrome. European Neurology . 2018;80(1/2):100–105.

12.   Baker T., Subramaniam A., Green C. Predictors of respiratory failure in patients with Guillain-Barre syndrome: a systematic review and meta-analysis. Medical Journal of Australia: Journal of the Australian Medical Association . 2018;208(4):181–95.

13.   Sonavane AD, Saigal S, Kathuria A, Choudhary NS., Saraf N. Guillain-Barré syndrome: rare extra-intestinal manifestation of hepatitis B. Clinical journal of gastroenterology . 2018;11(4):312–314.

14.   Liu S, Xiao Z, Lou M. Guillain-Barré syndrome in southern China: retrospective analysis of hospitalised patients from 14 provinces in the area south of the Huaihe River. Journal of Neurology, Neurosurgery & Psychiatry . 2018;89(6):618–626. doi: 10.1136/jnnp-2017-316930.

15.   van den Berg B., Storm E. F., Garssen M. J. P., Blomkwist-Markens P. H., Jacobs B. C. Clinical outcome of Guillain-Barré syndrome after prolonged mechanical ventilation. Journal of Neurology, Neurosurgery & Psychiatry . 2018;89(9):949–954.

16.   McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain−Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32(2):150-163.

17.   Wakerley BR, Soon D, Chan YC, Yuki N. Atypical Bickerstaff brainstem encephalitis: ataxic hypersomnolence without ophthalmoplegia. J Neurol Neurosurg Psychiatry. 2013;84(11):1206-1207.

18.   Yuki N, Kuwabara S, Koga M, Hirata K. Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common immunological profile. J Neurol Sci. 1999 Oct;168(2):121-6.

19.   Ropper AH. The Guillain–Barré syndrome. N Engl J Med. 1992 Apr;326(17):1130-6.

20.   Middleton A., Andrews A. W. Improvement during inpatient rehabilitation among older adults with Guillain-barre syndrome, multiple sclerosis, Parkinson disease, and stroke. American Journal of Physical Medicine and Rehabilitation . 2018;97(12):879–884.

21.   Brezovska K., Colzani M., Loshaj-Shala A., Poceva A., Panovska A. P., Suturkova L. Immunoproteomic identification of antigenic candidate Campylobacter jejuni and human peripheral nerve proteins involved in Guillain-Barre syndrome. Journal of Neuroimmunology: Official Bulletin of the Research Committee on Neuroimmunology of the World Federation of Neurology . 2018;317:77–83.

22.   Mandal J., Vanathi K., Baskar D., Dhodapkar R., Vanathi K. Antibodies to Zika virus, Campylobacter jejuni and gangliosides in Guillain-Barre syndrome: a prospective single-center study from southern India. Neurology India . 2018;66(5):1324–1331.

23.   Gumusyayla, Sadiye V., Gonul C., et al. Dynamic thiol-disulphide homeostasis in patients with Guillain-Barre Syndrome. Neurological Research: An Interdisciplinary Quarterly Journal . 2019;41(5):413–418.

24.   Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, et al. Regional variation of Guillain-Barré syndrome. Brain J Neurol. 2018;141:2866–2877.

25.   Frankle RT. Nutrition education in the medical school curriculum: A proposal for action: A curriculum design. Am J Clin Nutr. 1976;29:105–9.

26.   Dourado ME, Félix RH, da Silva WK, Queiroz JW, Jeronimo SM. Clinical characteristics of Guillain-Barré syndrome in a tropical country: A Brazilian experience. Acta Neurol Scand. 2012;125:47–53.

27.   Lin JJ, Hsia SH, Wang HS, Lyu RK, Chou ML, Hung PC, et al. Clinical variants of Guillain-Barré syndrome in children. Pediatr Neurol. 2012;47:91–6.

28.   Al Maawali SM, Al Shibani AY, Nadeem AS, Al-Salti AM. Guillain-Barre syndrome: demographics, clinical features, and outcome in a single tertiary care hospital. Oman Neurosci Riyadh Saudi Arab. 2020;25:369–374.

29.   Nagarajan V, Al-Shubaili A. Clinical and neurophysiological pattern of Guillain-Barré syndrome in Kuwait. Med Princ Pract Int J Kuwait Univ Health Sci Cent. 2006;15:120–125.

30.   Tian J, Cao C, Li T, Zhang K, Li P, Liu Y, et al. Electrophysiological Subtypes and Prognostic Factors of Guillain-Barre Syndrome in Northern China. Front Neurol. 2019;10:714.

31.   Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol. 1998;44:780–8.

32.   Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, et al. . Regional variation of Guillain-Barre syndrome. Brain. (2018) 141:2866–77.

33.   Ye Y, Wang K, Deng F, Xing Y. Electrophysiological subtypes and prognosis of Guillain-Barré syndrome in Northeastern China. Muscle Nerve. (2013) 47:68–71.

34.   van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014; 10: 469–82.

35.   Yadegari, S., Nafissi, S., & Kazemi, N. (2014). Comparison of electrophysiological findings in axonal and demyelinating Guillain-Barre syndrome. Iranian journal of neurology, 13(3), 138–143.

36.   Hiraga A, Mori M, Ogawara K, Kojima S, Kanesaka T, Misawa S, et al. Recovery patterns and long term prognosis for axonal Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2005;76(5):719–22.

37.   Gupta D, Nair M, Baheti NN, Sarma PS, Kuruvilla A. Electrodiagnostic and clinical aspects of Guillain-Barre syndrome: an analysis of 142 cases. J Clin Neuromuscul Dis. 2008;10(2):42–51.

38.   Burns TM. Guillain-Barre syndrome. Semin Neurol. 2008;28(2):152–67.

39.   Kuwabara S, Yuki N. Axonal Guillain-Barre syndrome: concepts and controversies. Lancet Neurol 2013; 12: 1180–8.

40.   Blaser MJ, Olivares A, Taylor DN, Cornblath DR, McKhann GM. Campylobacter serology in patients with Chinese paralytic syndrome. Lancet. 1991;338:308.